BV-AVD for bulky Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs (brentuximab vedotin, AVD chemotherapy) for people with newly diagnosed, bulky Hodgkin lymphoma that hasn't spread far. It aims to see if this treatment works well for larger tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have classic Hodgkin lymphoma that tests positive for CD30 (a protein on the cancer cells).
- You must have stage I or II Hodgkin lymphoma that shows up on a PET/CT scan.
- You must have a tumor that is at least 7 cm (about the size of a peach) in any direction.
- You must be 18 years old or older.
- You must be able to carry out most daily activities (not bedridden).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination drug treatment called BrECADD for people with Hodgkin lymphoma that has certain risk factors or is in a more advanced stage (stage 2B, 3, or 4). It aims to see if this treatment works well and is safe.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
This study tests a treatment plan for adults with Hodgkin lymphoma that has returned or did not respond to ABVD chemotherapy. It may help people with a higher-risk pattern of disease, as long as their organ function and overall health meet study limits.
This trial tests a combination of the targeted drug brentuximab vedotin with standard chemotherapy (doxorubicin, vinblastine, and dacarbazine) for adults with Stage 3 or 4 Hodgkin lymphoma who have not had previous treatment. It aims to see if this combination works well and is safe.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial is a survey study that looks at how brentuximab vedotin is used in children with Hodgkin lymphoma. It focuses on people whose tumor is CD30-positive and who have not had prior treatment, to see how the drug fits with a standard chemotherapy plan (AVD).
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.